Kojo S. J. Elenitoba-Johnson

Kojo S. J. Elenitoba-Johnson

Auto-generated profile, based on publicly available information

Kojo S. J. Elenitoba-Johnson

Memorial Sloan Kettering Cancer Center Department of Pathology and Laboratory Medicine New York, New York

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
RARita Alaggio
Rita Alaggio
CACatalina Amador
Catalina Amador
IAIoannis Anagnostopoulos
Ioannis Anagnostopoulos
AAAyoma D. Attygalle
Ayoma D. Attygalle
IAIguaracyra Barreto de Oliveira Araujo
Iguaracyra Barreto de Oliveira Araujo
WXWenbin Xiao
Wenbin Xiao
We herein present an overview of the upcoming 5thedition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4thedition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5thedition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms.

23 March 2017 in Blood
Verified
Journal Article
Open access
PDF file
DFDavid C. Fajgenbaum
David C. Fajgenbaum
TUThomas S. Uldrick
Thomas S. Uldrick
ABAdam Bagg
Adam Bagg
DFDale Frank
Dale Frank
DWDavid Wu
David Wu
MLMegan S. Lim
Megan S. Lim
Key Points: An international panel established the first ever diagnostic criteria for iMCD based on review of 244 clinical cases and 88 tissue samples. The criteria require multicentric lymphadenopathy with defined histopathology, ≥2 clinical/laboratory changes, and exclusion of iMCD mimics.

1 June 2001 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
CCCheryl M Coffin
Cheryl M Coffin
APAnkita Patel
Ankita Patel
SPSherrie Perkins
Sherrie Perkins
KEKojo S J Elenitoba-Johnson
Kojo S J Elenitoba-Johnson
EPElizabeth Perlman
Elizabeth Perlman
CGConstance A Griffin
Constance A Griffin

1 May 2013 in Neuron
Verified
Journal Article
Closed access
PTPeter K. Todd
Peter K. Todd
SOSeok Yoon Oh
Seok Yoon Oh
AKAmy Krans
Amy Krans
FHFang He
Fang He
CSChantal Sellier
Chantal Sellier
HPHenry L. Paulson
Henry L. Paulson

1 February 2019 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
CACharu Aggarwal
Charu Aggarwal
JTJeffrey C. Thompson
Jeffrey C. Thompson
TBTaylor A. Black
Taylor A. Black
SKSharyn I. Katz
Sharyn I. Katz
RFRyan Fan
Ryan Fan
ECErica L. Carpenter
Erica L. Carpenter
The development of targeted therapies has changed the treatment paradigm for non–small cell lung cancer (NSCLC).1 Molecularly targeted agents directed against driver and resistance mutations in EGFR [NG_007726.3], ALK [NG_009445.1], ROS1 [NG_033929.1], and BRAF [NG_007873.3] have improved clinical outcomes in patients harboring these genetic alterations.2,3 Indeed, for such patients, targeted therapy is the preferred treatment.4-6 The National Comprehensive Cancer Network treatment guidelines advocate actionable mutation screening as standard of care,7 but tumor tissue is often difficult to obtain or yields inadequate DNA, especially in the relapsed and metastatic settings.8,9 Clinically relevant mutations may also change during the course of treatment,10 an evolution that is difficult to monitor through tissue biopsy results alone. Spatial and temporal tumor heterogeneity make accurate assessment of resistance mutations based on biopsy of a single metastatic site challenging. A reliable method for noninvasive, clinically actionable mutation detection is, therefore, essential for the effective delivery of precision medicine for patients with NSCLC.

15 November 2018 in Blood
Verified
Journal Article
Open access
PDF file
FRFrits Van Rhee
Frits Van Rhee
PVPeter Voorhees
Peter Voorhees
ADAngela Dispenzieri
Angela Dispenzieri
AFAlexander Fosså
Alexander Fosså
GSGordan Srkalovic
Gordan Srkalovic
DFDavid C. Fajgenbaum
David C. Fajgenbaum
Castleman disease (CD) describes a group of heterogeneous hematologic disorders with characteristic histopathological features. CD can present with unicentric or multicentric (MCD) regions of lymph node enlargement. Some cases of MCD are caused by human herpesvirus-8 (HHV-8), whereas others are HHV-8–negative/idiopathic (iMCD). Treatment of iMCD is challenging, and outcomes can be poor because no uniform treatment guidelines exist, few systematic studies have been conducted, and no agreed upon response criteria have been described. The purpose of this paper is to establish consensus, evidence-based treatment guidelines based on the severity of iMCD to improve outcomes. An international Working Group of 42 experts from 10 countries was convened by the Castleman Disease Collaborative Network to establish consensus guidelines for the management of iMCD based on published literature, review of treatment effectiveness for 344 cases, and expert opinion. The anti–interleukin-6 monoclonal antibody siltuximab (or tocilizumab, if siltuximab is not available) with or without corticosteroids is the preferred first-line therapy for iMCD. In the most severe cases, adjuvant combination chemotherapy is recommended. Additional agents are recommended, tailored by disease severity, as second- and third-line therapies for treatment failures. Response criteria were formulated to facilitate the evaluation of treatment failure or success. These guidelines should help treating physicians to stratify patients based on disease severity in order to select the best available therapeutic option. An international registry for patients with CD (ACCELERATE, #NCT02817997) was established in October 2016 to collect patient outcomes to increase the evidence base for selection of therapies in the future.